New Analysis Confirms Brain-Loss Benefits With Teriflunomide (Aubagio)
SIENA shows the drug reduces brain shrinkage in MS over 2 years BARCELONA — Although earlier MRI data didn’t find…
An MS Patient Advocate’s Exclusive Interview on Primary Progressive MS ORATORIO trial results with Peter Chin, MD, Principal Medical Director for Genentech-Roche Global Neuroscience Development
Interview on the PPMS ORATORIO Study By Laura Kolaczkowski—October 11, 2015 The interview begins below all the legalities needed People with primary…
Stuart Schlossman
Teriflunomide (AUBAGIO) Slows Brain Atrophy in Relapsing Multiple Sclerosis
Oct 9, 2015 BARCELONA — A reanalysis of phase III data on teriflunomide (Aubagio) shows that both doses of the…
Stuart Schlossman
Tysabri vs. Gilenya: Studies Conflict on Which Is Superior
Is natalizumab better than fingolimod? Flip a coin by John Gever Managing Editor, MedPage Today BARCELONA — Results from two European…
Stuart Schlossman
THE ROLE OF B AND T CELLS IN MULTIPLE SCLEROSIS – Shining a LIGHT on MS
SHINING A LIGHT ON MULTIPLE SCLEROSIS More than 2 million people worldwide are affected by multiple sclerosis (MS).1 Genentech is committed to understanding MS. Learn…
Stuart Schlossman
Tried-and-True Antibiotic May Block Conversion to MS
Minocycline seemed to reduce progression to multiple sclerosis after first demyelinating event BARCELONA — After a first demyelinating event, a…
Stuart Schlossman
Ocrelizumab: Experts Question Magnitude of Benefit in PPMS
ORATORIO trial results positive, but not impressive enough BARCELONA — Enthusiasm for ocrelizumab was tempered after positive results from the…
Stuart Schlossman
Genzyme Provides Update on Lemtrada for Patients with Relapsing-Remitting Multiple Sclerosis, ECTRIMS 2015
Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS).…
Stuart Schlossman
PPMS Update: Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
Ocrelizumab showed superiority to interferon beta-1a (Rebif®) in two identical Phase III studies in people with relapsing multiple sclerosis (MS),…
Stuart Schlossman
Find a Lemtrada Learning Program-event near you
> Learn what an expert has to say about an infusion treatment for relapsing MS Trouble viewing? View as a…
Stuart Schlossman
